Dalton Pharma Services has entered into a manufacturing services agreement with Clarity Pharmaceuticals based in Sydney, Australia. Dalton will provide cGMP chemistry manufacturing, scale up, aseptic fill/finish services and analytical support for Clarity’s PET-based companion diagnostics and radio-immunotherapeutics development program.
“Our expert capabilities in the manufacture of complex chemical products, including conjugation under sterile cGMP conditions and our strength in aseptic filling, solidified the manufacturing agreement,” said Peter Pekos, chief executive officer of Dalton. “We are excited to have the opportunity to work with Clarity in bringing this breakthrough imaging technology from a research setting to the drug development industry. Adding Clarity to our growing list of strategic relationships with innovative clients is an important milestone for Dalton.”
Dr. Matt Harris, managing director of Clarity, said, “The alliance with Dalton is a key part of our ongoing success in making our novel diagnostic tools quickly available to the pharmaceutical development industry. Therapeutic targeting is one of the biggest opportunities for the advancement of novel treatments today. Clarity is pleased to launch this technology for use by the global pharmaceutical community.”